A major 18-month drug trial gets under way this week to see whether a blood pressure medication can slow or halt the progression of Alzheimer’s disease symptoms.
An Irish medical researcher, Prof. Brian Lawlor, is co-ordinating the international trial, Nilvad (nilvadipine in Alzheimer’s disease),
which involves nine countries. For more information click here….
The plaque deposits in the brain of Alzheimer’s patients are surrounded by the brain’s own immune cells, the microglia.
This was already recognized by Alois Alzheimer more than one hundred years ago. But until today it still remains unclear what role microglia play in Alzheimer’s disease. Do they help to break down the plaque deposit? For more on this subject click here…
Two new studies show, insight into genes that play a key role in disrupting immune system pathways in the brains of people with Alzheimer’s disease could offer a potential target for new drugs against the disease. If interested in the full article, click here….
Eli Lilly and Co. has acquired two investigational PET imaging agents from Siemens Healthcare in an effort to boost its commitment to Alzheimer’s disease research and development. Both tracers have been clinically proven to selectively target neurofibrillary tangles (NFTS), or tau, a diagnostic biomarker for Alzheimer’s disease. To read more of this article….
The Clarity technique ushers in a new era of brain imaging, offering hope for improving the study of such neurological disorders as autism, schizophrenia, Alzheimer’s disease and Parkinson’s disease. Read full article…